Chardan Capital affirms Medicines Company (Nasdaq: MDCO) with a Buy rating and $50 price target after the company and Alnylam ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital NotesNovember 12, 2015 7:43 AM Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1November 11, 2015 10:47 AM Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual HypercholestNovember 11, 2015 10:45 AM Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 TodayNovember 11, 2015 8:23 AM Form 10-Q MEDICINES CO /DE For: Sep 30November 9, 2015 4:09 PM